Inventor · disambiguated record
Martin Duplessis
Also filed as: DUPLESSIS MARTIN
29 granted patents·13 pending applications·121 citations·filing 2007–2025
95Inventor score
Files withC4 THERAPEUTICS INC13CONSTELLATION PHARMACEUTICALS INC8HOFFMANN LA ROCHE8GENENTECH INC6BOEHRINGER INGELHEIM INT4
Top patents by PatentIndex Score
42 records- 0196US12209091B2Isoindolinone derivatives as selective allosteric inhibitors of Egfr mutant cancersHOFFMANN LA ROCHE·Filed 2020·Granted Jan 28, 2025·7 cites·30 claims
- 0295US12048747B2Substituted piperidine Degronimers for Target Protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Jul 30, 2024·4 cites·22 claims
- 0395US11673902B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2022·Granted Jun 13, 2023·3 cites·29 claims
- 0495US8349839B2Inhibitors of HIV replicationBOEHRINGER INGELHEIM INT·Filed 2010·Granted Jan 8, 2013·43 cites·14 claims
- 0594US11708354B22-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compoundsHOFFMANN LA ROCHE·Filed 2020·Granted Jul 25, 2023·3 cites·16 claims
- 0694US11459335B2N/O-linked Degrons and Degronimers for protein degradationC4 THERAPEUTICS INC·Filed 2019·Granted Oct 4, 2022·8 cites·23 claims
- 0793US12371442B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2023·Granted Jul 29, 2025·1 cites·28 claims
- 0893US9085583B2Modulators of methyl modifying enzymes, compositions and uses thereofCONSTELLATION—PHARMACEUTICALS INC·Filed 2013·Granted Jul 21, 2015·18 cites·14 claims
- 0991US9371331B2Modulators of methyl modifying enzymes, compositions and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2015·Granted Jun 21, 2016·8 cites·9 claims
- 1087US12180225B2N/O-linked degrons and degronimers for protein degradationC4 THERAPEUTICS INC·Filed 2022·Granted Dec 31, 2024·1 cites·19 claims
- 1187US10882848B22-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compoundsHOFFMANN LA ROCHE·Filed 2019·Granted Jan 5, 2021·3 cites·15 claims
- 1287US10308614B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted Jun 4, 2019·4 cites·21 claims
- 1386US11117890B2Substituted isoindole allosteric EGFR inhibitorsHOFFMANN LA ROCHE·Filed 2019·Granted Sep 14, 2021·3 cites·21 claims
- 1486US10016405B2Modulators of methyl modifying enzymes, compositions and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2016·Granted Jul 10, 2018·3 cites·4 claims
- 1585US9980952B2Modulators of methyl modifying enzymes, compositions and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2016·Granted May 29, 2018·3 cites·8 claims
- 1685US9969716B2Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2014·Granted May 15, 2018·4 cites·21 claims
- 1781US12486253B2Therapeutics for the degradation of mutant BRAFC4 THERAPEUTICS INC·Filed 2024·Granted Dec 2, 2025·0 cites·4 claims
- 1880US12486290B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2025·Granted Dec 2, 2025·0 cites·30 claims
- 1980US10526287B2LSD1 inhibitors and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2016·Granted Jan 7, 2020·2 cites·22 claims
- 2080US2025127903A1Substituted piperidine degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2178US10239861B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted Mar 26, 2019·2 cites·7 claims
- 2276US12441740B2N/O-linked degrons and degronimers for protein degradationC4 THERAPEUTICS INC·Filed 2024·Granted Oct 14, 2025·0 cites·19 claims
- 2370US9708332B2Respiratory syncytial virus inhibitorsMEDIVIR AB·Filed 2013·Granted Jul 18, 2017·1 cites·15 claims
- 2470US2024199581A1Therapeutics for the degradation of mutant brafC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2566US2019125737A1Modulators of methyl modifying enzymes, compositions and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2664US2015376190A1Modulators of methyl modifying enzymes, compositions and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2763US2024158418A1EGFR Degraders to Treat Cancer Metastasis to the Brain or CNSC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2862US2019076539A1Amine-linked c3-glutarimide degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2960US2023372496A1Tricyclic heterobifunctional compounds for degradation of targeted proteinsC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3051US2024383886A1Protein Tyrosine Phosphatase Degraders and Methods of Use ThereofCALICO LIFE SCIENCES LLC·Filed 2020·Application pending·0 cites
- 3151US2020308171A1Bifunctional inhibitors with egfr having a e3 ubiquitin ligase moietyHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3251US2023002367A1Bifunctional compoundsHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3351US2023024096A1Bifunctional compounds for the treatment of cancerHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3451US2025177396A1Polo-like kinase 4 (plk4) inhibitors, pharmaceutical compositions, methods of preparation and uses thereofREPARE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3551US2020361930A1Bifunctional molecules that degrade egfrHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3649US9334249B2Inhibitors of cytomegalovirusBOEHRINGER INGELHEIM INT·Filed 2013·Granted May 10, 2016·0 cites·11 claims
- 3748US9399645B2Inhibitors of HIV replicationBOEHRINGER INGELHEIM INT·Filed 2012·Granted Jul 26, 2016·0 cites·8 claims
- 3848US8039638B2Inhibitors of HIV replicationBOEHRINGER INGELHEIM INT·Filed 2007·Granted Oct 18, 2011·0 cites·21 claims
- 3947US10358437B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted Jul 23, 2019·0 cites·9 claims
- 4041US10301253B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted May 28, 2019·0 cites·21 claims
- 4140US10202378B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted Feb 12, 2019·0 cites·18 claims
- 4238US10155764B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted Dec 18, 2018·0 cites·23 claims
Join the waitlist — get patent alerts
Get an alert when Martin Duplessis files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →